Compare CAPL & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAPL | ALVO |
|---|---|---|
| Founded | 1992 | 2013 |
| Country | United States | Luxembourg |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 889.1M | 1.0B |
| IPO Year | 2012 | 2021 |
| Metric | CAPL | ALVO |
|---|---|---|
| Price | $22.76 | $5.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 41.9K | ★ 973.6K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 9.96% | N/A |
| EPS Growth | ★ 96.15 | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $1,869,806,000.00 | N/A |
| Revenue This Year | N/A | $13.28 |
| Revenue Next Year | $2.80 | $18.63 |
| P/E Ratio | $29.74 | ★ $18.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.67 | $2.94 |
| 52 Week High | $24.63 | $9.25 |
| Indicator | CAPL | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 49.16 | 70.45 |
| Support Level | $22.37 | $3.10 |
| Resistance Level | $24.63 | $5.44 |
| Average True Range (ATR) | 0.49 | 0.26 |
| MACD | -0.09 | 0.00 |
| Stochastic Oscillator | 24.70 | 78.70 |
CrossAmerica Partners LP is engaged in the wholesale distribution of motor fuel and the ownership and leasing of real estate used in the retail distribution of motor fuel. The company operates through two business segments, namely Wholesale and Retail. The Wholesale segment is a key revenue driver and includes the wholesale distribution of motor fuel to lessee dealers, independent dealers, commission agents, DMS, Circle K, and through company-operated retail sites. The Retail segment includes the sale of convenience merchandise items, the retail sale of motor fuel at company-operated retail sites, and the retail sale of motor fuel at retail sites operated by commission agents.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.